



## Clinical trial results:

### A 52-Week Phase 3 Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety and Tolerability of PF-04950615 in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events

#### Summary

EudraCT number	2014-000478-20
Trial protocol	FI GB SE CZ NL PL
Global end of trial date	10 July 2017

#### Results information

Result version number	v2 (current)
This version publication date	22 July 2018
First version publication date	09 July 2017
Version creation reason	

#### Trial information

##### Trial identification

Sponsor protocol code	B1481045
-----------------------	----------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02100514
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	Pfizer, Inc.
Sponsor organisation address	235 E 42nd Street, New York, United States, NY 10017
Public contact	Pfizer ClinicalTrials.gov Call Center, Pfizer, Inc., 001 8007181021, ClinicalTrials.gov_Inquiries@pfizer.com
Scientific contact	Pfizer ClinicalTrials.gov Call Center, Pfizer, Inc., 001 8007181021, ClinicalTrials.gov_Inquiries@pfizer.com

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	02 March 2018
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	10 July 2017
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

To demonstrate a superior low-density lipoprotein cholesterol (LDL-C) lowering effect of Bococizumab (PF-04950615) 150 milligram (mg) administered by the subcutaneous (SC) route every 2 weeks (Q2W) compared to placebo, in subjects with primary hyperlipidemia or mixed dyslipidemia at high or very high risk for cardiovascular events receiving statin therapy and whose LDL-C is greater or equal to ( $\geq$ ) 100 milligram per deciliter (mg/dL) (2.59 millimole per liter [mmol/L]).

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and in compliance with all International Council for Harmonization (ICH) Good Clinical Practice (GCP) Guidelines. All the local regulatory requirements pertinent to safety of trials subjects were followed.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	28 October 2014
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Canada: 79
Country: Number of subjects enrolled	Czech Republic: 35
Country: Number of subjects enrolled	Finland: 3
Country: Number of subjects enrolled	Korea, Republic of: 6
Country: Number of subjects enrolled	Netherlands: 38
Country: Number of subjects enrolled	Norway: 17
Country: Number of subjects enrolled	Poland: 71
Country: Number of subjects enrolled	Puerto Rico: 7
Country: Number of subjects enrolled	Singapore: 6
Country: Number of subjects enrolled	Sweden: 14
Country: Number of subjects enrolled	United Kingdom: 24
Country: Number of subjects enrolled	United States: 446
Worldwide total number of subjects	746
EEA total number of subjects	202

Notes:

<b>Subjects enrolled per age group</b>	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	429
From 65 to 84 years	315
85 years and over	2

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

This study was conducted at multiple sites from 28 October 2014 to 15 July 2016 for the Treatment Period and up to 10 July 2017 for the Extension Period.

### Period 1

Period 1 title	Treatment Period
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Carer

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Treatment Period: Placebo

Arm description:

Subjects received placebo matched to Bococizumab (PF--04950615) subcutaneous injection once every 2 weeks up to Week 52. Subjects were followed up to Week 58.

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

Subjects received placebo matched to Bococizumab (PF-04950615) subcutaneous injection once every 2 weeks over a period of 52 weeks.

<b>Arm title</b>	Treatment Period: Bococizumab (PF--04950615) 150 mg
------------------	---

Arm description:

Subjects received Bococizumab (PF--04950615) 150 mg subcutaneous injection once every 2 weeks up to Week 52. Subjects were followed up to Week 58.

Arm type	Experimental
Investigational medicinal product name	Bococizumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

Subjects received Bococizumab (PF-04950615) 150 mg subcutaneous injection once every 2 weeks over a period of 52 weeks.

Number of subjects in period 1	Treatment Period: Placebo	Treatment Period: Bococizumab (PF-- 04950615) 150 mg
Started	247	499
Completed	218	425
Not completed	29	74
Consent withdrawn by subject	12	37
Did Not Meet Entrance Criteria	-	1
Death	2	2
Adverse event	-	5
Unspecified	9	11
Lost to follow-up	5	17
Protocol deviation	1	1

## Period 2

Period 2 title	Extension Period
Is this the baseline period?	No
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

## Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Extension Period: Placebo

### Arm description:

Subjects randomized to Placebo arm in treatment period and consented for extension period after Week 58 follow-up visit, were followed for serious adverse events (SAEs) and concomitant medications up to Week 110.

Arm type	No intervention
No investigational medicinal product assigned in this arm	

<b>Arm title</b>	Extension Period: Bococizumab ADA positive
------------------	--

### Arm description:

Subjects randomized to Bococizumab in treatment period were classified as either ADA positive or ADA negative based on their ADA assessment at Week 58 follow-up visit. In extension period, subjects who were ADA positive and consented for extension period were assessed for ADA and LDL-C direct measurement until ADA titers were no longer detectable or had returned to baseline titer (less than or equal to 1.58 [log2] units above a positive baseline titer) or until Week 110 along with SAEs and concomitant medication, from Week 58 follow up visit to Week 110.

Arm type	No intervention
No investigational medicinal product assigned in this arm	

<b>Arm title</b>	Extension Period: Bococizumab ADA negative
------------------	--

### Arm description:

Subjects randomized to Bococizumab in treatment period were classified as either ADA positive or ADA negative based on their Week 58 follow-up ADA assessment. Subjects who were ADA negative and consented for extension period were followed for SAEs and concomitant medication, from Week 58 follow up visit to Week 110.

Arm type	No intervention
No investigational medicinal product assigned in this arm	

Number of subjects in period 2 <sup>[1]</sup>	Extension Period: Placebo	Extension Period: Bococizumab ADA positive	Extension Period: Bococizumab ADA negative
Started	44	33	56
Completed	42	33	56
Not completed	2	0	0
Consent withdrawn by subject	2	-	-

Notes:

[1] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.

Justification: Only subjects who consented for the extension period were followed in the extension period.

## Baseline characteristics

### Reporting groups

Reporting group title	Treatment Period: Placebo
Reporting group description:	
Subjects received placebo matched to Bococizumab (PF--04950615) subcutaneous injection once every 2 weeks up to Week 52. Subjects were followed up to Week 58.	
Reporting group title	Treatment Period: Bococizumab (PF--04950615) 150 mg
Reporting group description:	
Subjects received Bococizumab (PF--04950615) 150 mg subcutaneous injection once every 2 weeks up to Week 52. Subjects were followed up to Week 58.	

Reporting group values	Treatment Period: Placebo	Treatment Period: Bococizumab (PF-- 04950615) 150 mg	Total
Number of subjects	247	499	746
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	144	285	429
From 65-84 years	102	213	315
85 years and over	1	1	2
Age Continuous Units: years			
arithmetic mean	61.7	61.5	
standard deviation	± 10.0	± 9.9	-
Gender, Male/Female Units: Subjects			
Female	107	223	330
Male	140	276	416

## End points

### End points reporting groups

Reporting group title	Treatment Period: Placebo
Reporting group description: Subjects received placebo matched to Bococizumab (PF--04950615) subcutaneous injection once every 2 weeks up to Week 52. Subjects were followed up to Week 58.	
Reporting group title	Treatment Period: Bococizumab (PF--04950615) 150 mg
Reporting group description: Subjects received Bococizumab (PF--04950615) 150 mg subcutaneous injection once every 2 weeks up to Week 52. Subjects were followed up to Week 58.	
Reporting group title	Extension Period: Placebo
Reporting group description: Subjects randomized to Placebo arm in treatment period and consented for extension period after Week 58 follow-up visit, were followed for serious adverse events (SAEs) and concomitant medications up to Week 110.	
Reporting group title	Extension Period: Bococizumab ADA positive
Reporting group description: Subjects randomized to Bococizumab in treatment period were classified as either ADA positive or ADA negative based on their ADA assessment at Week 58 follow-up visit. In extension period, subjects who were ADA positive and consented for extension period were assessed for ADA and LDL-C direct measurement until ADA titers were no longer detectable or had returned to baseline titer (less than or equal to 1.58 [log2] units above a positive baseline titer) or until Week 110 along with SAEs and concomitant medication, from Week 58 follow up visit to Week 110.	
Reporting group title	Extension Period: Bococizumab ADA negative
Reporting group description: Subjects randomized to Bococizumab in treatment period were classified as either ADA positive or ADA negative based on their Week 58 follow-up ADA assessment. Subjects who were ADA negative and consented for extension period were followed for SAEs and concomitant medication, from Week 58 follow up visit to Week 110.	

### Primary: Percent Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) at Week 12

End point title	Percent Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) at Week 12
End point description: Full analysis set (FAS) included all subjects who were randomized. Here, "Number of subjects analyzed (N)" signifies number of subjects who were evaluable for this endpoint.	
End point type	Primary
End point timeframe: Baseline, Week 12	

End point values	Treatment Period: Placebo	Treatment Period: Bococizumab (PF--04950615) 150 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	235	468		
Units: percent change				



arithmetic mean (standard deviation)	-0.8 ( $\pm$ 17.61)	-50.8 ( $\pm$ 29.81)		
--------------------------------------	---------------------	----------------------	--	--

## Statistical analyses

<b>Statistical analysis title</b>	Placebo vs PF--04950615 150 mg
Statistical analysis description:	
Least square (LS) mean difference and associated 95% confidence interval (CI), and p-value were derived from an mixed effect model repeat measurement (MMRM) model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.	
Comparison groups	Treatment Period: Placebo v Treatment Period: Bococizumab (PF--04950615) 150 mg
Number of subjects included in analysis	703
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	MMRM
Parameter estimate	LS mean difference compared to placebo
Point estimate	-49.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-54
upper limit	-45.8
Variability estimate	Standard error of the mean
Dispersion value	2.09

## Secondary: Percent Change From Baseline in Fasting Total Cholesterol (TC) at Week 12, 24 and 52

End point title	Percent Change From Baseline in Fasting Total Cholesterol (TC) at Week 12, 24 and 52
End point description:	
FAS included all subjects who were randomized. Here, "n" signifies number of subjects who were evaluable at the specified time points.	
End point type	Secondary
End point timeframe:	
Baseline, Week 12, 24, 52	

End point values	Treatment Period: Placebo	Treatment Period: Bococizumab (PF--04950615) 150 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	247	499		
Units: percent change				
arithmetic mean (standard deviation)				
Week 12 (n =236, 469)	-2.2 (± 13.41)	-35.4 (± 20.93)		
Week 24 (n =237, 463)	-3.1 (± 15.79)	-32.9 (± 23.06)		
Week 52 (n =221, 425)	-5.0 (± 17.22)	-29.0 (± 22.08)		

## Statistical analyses

Statistical analysis title	Placebo vs PF--04950615 150 mg
Statistical analysis description:	
Week 12: LS mean difference and associated 95% CI and p-value were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.	
Comparison groups	Treatment Period: Placebo v Treatment Period: Bococizumab (PF--04950615) 150 mg
Number of subjects included in analysis	746
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	MMRM
Parameter estimate	LS mean difference compared to placebo
Point estimate	-33.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-36.1
upper limit	-30.2
Variability estimate	Standard error of the mean
Dispersion value	1.48

Statistical analysis title	Placebo vs PF--04950615 150 mg
Statistical analysis description:	
Week 24: LS mean difference and associated 95% CI were derived from an MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.	
Comparison groups	Treatment Period: Placebo v Treatment Period: Bococizumab (PF--04950615) 150 mg

Number of subjects included in analysis	746
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	LS mean difference compared to placebo
Point estimate	-29.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-32.8
upper limit	-26.3
Variability estimate	Standard error of the mean
Dispersion value	1.66

<b>Statistical analysis title</b>	Placebo vs PF--04950615 150 mg
-----------------------------------	--------------------------------

Statistical analysis description:

Week 52: LS mean difference and associated 95% CI were derived from an MMRM model with fixed effects for treatment group, visit, treatment group\*visit interaction, baseline value, baseline value\*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.

Comparison groups	Treatment Period: Placebo v Treatment Period: Bococizumab (PF--04950615) 150 mg
Number of subjects included in analysis	746
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	LS mean difference compared to placebo
Point estimate	-23.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-27
upper limit	-20.5
Variability estimate	Standard error of the mean
Dispersion value	1.65

## **Secondary: Percent Change From Baseline in Fasting Apolipoprotein B (ApoB) at Week 12, 24 and 52**

End point title	Percent Change From Baseline in Fasting Apolipoprotein B (ApoB) at Week 12, 24 and 52
-----------------	---

End point description:

FAS included all subjects who were randomized. Here, "n" signifies number of subjects who were evaluable at the specified time points.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week 12, 24, 52

<b>End point values</b>	Treatment Period: Placebo	Treatment Period: Bococizumab (PF--04950615) 150 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	247	499		
Units: percent change				
arithmetic mean (standard deviation)				
Week 12 (n =234, 467)	-0.6 (± 16.70)	-46.5 (± 28.87)		
Week 24 (n =236, 461)	-2.1 (± 18.66)	-43.5 (± 32.26)		
Week 52 (n =221, 425)	-4.4 (± 20.77)	-37.3 (± 29.59)		

## Statistical analyses

<b>Statistical analysis title</b>	Placebo vs PF--04950615 150 mg
Statistical analysis description:	
Week 12: LS mean difference and associated 95% CI, and p-value were derived from an MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.	
Comparison groups	Treatment Period: Placebo v Treatment Period: Bococizumab (PF--04950615) 150 mg
Number of subjects included in analysis	746
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	MMRM
Parameter estimate	LS mean difference compared to placebo
Point estimate	-45.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-49.6
upper limit	-41.6
Variability estimate	Standard error of the mean
Dispersion value	2.04

<b>Statistical analysis title</b>	Placebo vs PF--04950615 150 mg
Statistical analysis description:	
Week 24: LS mean difference and associated 95% CI, were derived from an MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.	
Comparison groups	Treatment Period: Placebo v Treatment Period: Bococizumab (PF--04950615) 150 mg

Number of subjects included in analysis	746
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	LS mean difference compared to placebo
Point estimate	-40.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-45.3
upper limit	-36.5
Variability estimate	Standard error of the mean
Dispersion value	2.26

<b>Statistical analysis title</b>	Placebo vs PF--04950615 150 mg
-----------------------------------	--------------------------------

Statistical analysis description:

Week 52: LS mean difference and associated 95% CI, were derived from an MMRM model with fixed effects for treatment group, visit, treatment group\*visit interaction, baseline value, baseline value\*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.

Comparison groups	Treatment Period: Placebo v Treatment Period: Bococizumab (PF--04950615) 150 mg
Number of subjects included in analysis	746
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	LS mean difference compared to placebo
Point estimate	-32.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-36.7
upper limit	-28.2
Variability estimate	Standard error of the mean
Dispersion value	2.17

### **Secondary: Percent Change From Baseline in Fasting Non High Density Lipoprotein Cholesterol (non HDL-C) at Week 12, 24 and 52**

End point title	Percent Change From Baseline in Fasting Non High Density Lipoprotein Cholesterol (non HDL-C) at Week 12, 24 and 52
-----------------	--

End point description:

FAS included all subjects who were randomized. Here, "n" signifies number of subjects who were evaluable at the specified time points.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week 12, 24, 52

<b>End point values</b>	Treatment Period: Placebo	Treatment Period: Bococizumab (PF--04950615) 150 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	247	499		
Units: percent change				
arithmetic mean (standard deviation)				
Week 12 (n =236, 469)	-2.6 (± 17.57)	-47.6 (± 28.36)		
Week 24(n =237, 463)	-3.8 (± 20.63)	-44.7 (± 30.83)		
Week 52 (n =221, 425)	-6.4 (± 22.70)	-39.5 (± 29.36)		

## Statistical analyses

<b>Statistical analysis title</b>	Placebo vs PF--04950615 150 mg
Statistical analysis description:	
Week 12: LS mean difference and associated 95% CI and p-value were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.	
Comparison groups	Treatment Period: Placebo v Treatment Period: Bococizumab (PF--04950615) 150 mg
Number of subjects included in analysis	746
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	MMRM
Parameter estimate	LS mean difference compared to placebo
Point estimate	-44.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-48.8
upper limit	-41
Variability estimate	Standard error of the mean
Dispersion value	1.99

<b>Statistical analysis title</b>	Placebo vs PF--04950615 150 mg
Statistical analysis description:	
Week 24: LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.	
Comparison groups	Treatment Period: Placebo v Treatment Period: Bococizumab (PF--04950615) 150 mg

Number of subjects included in analysis	746
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	LS mean difference compared to placebo
Point estimate	-40.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-44.8
upper limit	-36.1
Variability estimate	Standard error of the mean
Dispersion value	2.21

<b>Statistical analysis title</b>	Placebo vs PF--04950615 150 mg
-----------------------------------	--------------------------------

Statistical analysis description:

Week 52: LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group\*visit interaction, baseline value, baseline value\*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.

Comparison groups	Treatment Period: Placebo v Treatment Period: Bococizumab (PF--04950615) 150 mg
Number of subjects included in analysis	746
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	LS mean difference compared to placebo
Point estimate	-32.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-37
upper limit	-28.4
Variability estimate	Standard error of the mean
Dispersion value	2.2

### **Secondary: Percent Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) by Triglycerides Cut-off of Less Than (<) 200 Milligram per Deciliter (mg/dL) at Week 12, 24 and 52**

End point title	Percent Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) by Triglycerides Cut-off of Less Than (<) 200 Milligram per Deciliter (mg/dL) at Week 12, 24 and 52
-----------------	---

End point description:

A subset of FAS included all participants who were randomized and had TG <200 mg/dL at pre-randomization. Here, "n" signifies number of subjects who were evaluable at the specified time points.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week 12, 24, 52

<b>End point values</b>	Treatment Period: Placebo	Treatment Period: Bococizumab (PF--04950615) 150 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	164	331		
Units: percent change				
arithmetic mean (standard deviation)				
Week 12 (n =158, 313)	0.5 (± 16.61)	-51.1 (± 30.43)		
Week 24 (n =159, 311)	-1.6 (± 21.68)	-48.4 (± 33.67)		
Week 52 (n =148, 292)	-4.2 (± 24.11)	-42.2 (± 33.75)		

## Statistical analyses

<b>Statistical analysis title</b>	Placebo vs PF--04950615 150 mg
Statistical analysis description:	
Week 12: LS mean difference and associated 95% CI and p-value were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction and geographical region. An unstructured variance covariance matrix was used.	
Comparison groups	Treatment Period: Placebo v Treatment Period: Bococizumab (PF--04950615) 150 mg
Number of subjects included in analysis	495
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	MMRM
Parameter estimate	LS mean difference compared to placebo
Point estimate	-51.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-56.7
upper limit	-46.6
Variability estimate	Standard error of the mean
Dispersion value	2.59

<b>Statistical analysis title</b>	Placebo vs PF--04950615 150 mg
Statistical analysis description:	
Week 24: LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction and geographical region. An unstructured variance covariance matrix was used.	
Comparison groups	Treatment Period: Placebo v Treatment Period: Bococizumab



	(PF--04950615) 150 mg
Number of subjects included in analysis	495
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	LS mean difference compared to placebo
Point estimate	-46.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-52.2
upper limit	-40.6
Variability estimate	Standard error of the mean
Dispersion value	2.94

<b>Statistical analysis title</b>	Placebo vs PF--04950615 150 mg
Statistical analysis description:	
Week 52: LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction and geographical region. An unstructured variance covariance matrix was used.	
Comparison groups	Treatment Period: Placebo v Treatment Period: Bococizumab (PF--04950615) 150 mg
Number of subjects included in analysis	495
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	LS mean difference compared to placebo
Point estimate	-37.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-43.3
upper limit	-31.4
Variability estimate	Standard error of the mean
Dispersion value	3.03

**Secondary: Percent Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) by Triglycerides Cut-off of Greater Than or Equal to ( $\geq$ ) 200 Milligram per Deciliter (mg/dL) at Week 12, 24 and 52**

End point title	Percent Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) by Triglycerides Cut-off of Greater Than or Equal to ( $\geq$ ) 200 Milligram per Deciliter (mg/dL) at Week 12, 24 and 52
End point description:	
A subset of FAS included all participants who were randomized and had TG $\geq$ 200 mg/dL at pre-randomization. Here, "n" signifies number of subjects who were evaluable at the specified time points.	
End point type	Secondary
End point timeframe:	
Baseline, Week 12, 24, 52	

End point values	Treatment Period: Placebo	Treatment Period: Bococizumab (PF--04950615) 150 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	83	168		
Units: percent change				
arithmetic mean (standard deviation)				
Week 12 (n =77,155)	-3.4 (± 19.34)	-50.1 (± 28.62)		
Week 24 (n =77,150)	-5.7 (± 21.67)	-45.8 (± 33.13)		
Week 52 (n =74,133)	-5.7 (± 23.78)	-40.9 (± 30.25)		

## Statistical analyses

Statistical analysis title	Placebo vs PF--04950615 150 mg
Statistical analysis description:	
Week 12: LS mean difference and associated 95% CI and p-value were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction and geographical region. An unstructured variance covariance matrix was used.	
Comparison groups	Treatment Period: Placebo v Treatment Period: Bococizumab (PF--04950615) 150 mg
Number of subjects included in analysis	251
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	MMRM
Parameter estimate	LS mean difference compared to placebo
Point estimate	-46.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-53.7
upper limit	-39.5
Variability estimate	Standard error of the mean
Dispersion value	3.59

Statistical analysis title	Placebo vs PF--04950615 150 mg
Statistical analysis description:	
Week 24: LS mean difference and associated 95% CI were derived from an MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction and geographical region. An unstructured variance covariance matrix was used.	
Comparison groups	Treatment Period: Placebo v Treatment Period: Bococizumab

	(PF--04950615) 150 mg
Number of subjects included in analysis	251
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	LS mean difference compared to placebo
Point estimate	-39.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-47.9
upper limit	-31.6
Variability estimate	Standard error of the mean
Dispersion value	4.12

<b>Statistical analysis title</b>	Placebo vs PF--04950615 150 mg
Statistical analysis description:	
Week 52: LS mean difference and associated 95% CI were derived from an MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction and geographical region. An unstructured variance covariance matrix was used.	
Comparison groups	Treatment Period: Placebo v Treatment Period: Bococizumab (PF--04950615) 150 mg
Number of subjects included in analysis	251
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	LS mean difference compared to placebo
Point estimate	-33.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-41.3
upper limit	-25.5
Variability estimate	Standard error of the mean
Dispersion value	4.02

### **Secondary: Percent Change From Baseline in Fasting Lipoprotein (A) (Lp[A]) at Week 12, 24 and 52**

End point title	Percent Change From Baseline in Fasting Lipoprotein (A) (Lp[A]) at Week 12, 24 and 52
End point description:	
FAS included all subjects who were randomized. Here, "n" signifies number of subjects who were evaluable at the specified time points.	
End point type	Secondary
End point timeframe:	
Baseline, Week 12, 24, 52	

<b>End point values</b>	Treatment Period: Placebo	Treatment Period: Bococizumab (PF--04950615) 150 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	247	499		
Units: percent change				
arithmetic mean (standard deviation)				
Week 12 (n =235, 469)	4.9 (± 54.24)	-25.7 (± 29.45)		
Week 24 (n =235, 463)	5.9 (± 50.52)	-21.3 (± 34.42)		
Week 52 (n =221, 425)	27.9 (± 374.64)	-21.5 (± 32.61)		

## Statistical analyses

<b>Statistical analysis title</b>	Placebo vs PF--04950615 150 mg
Statistical analysis description:	
Week 12: LS mean difference and associated 95% CI and p-value were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.	
Comparison groups	Treatment Period: Placebo v Treatment Period: Bococizumab (PF--04950615) 150 mg
Number of subjects included in analysis	746
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	MMRM
Parameter estimate	LS mean difference compared to placebo
Point estimate	-30.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-36.9
upper limit	-24.6
Variability estimate	Standard error of the mean
Dispersion value	3.14

<b>Statistical analysis title</b>	Placebo vs PF--04950615 150 mg
Statistical analysis description:	
Week 24: LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.	
Comparison groups	Treatment Period: Placebo v Treatment Period: Bococizumab (PF--04950615) 150 mg

Number of subjects included in analysis	746
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	LS mean difference compared to placebo
Point estimate	-27.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-33.9
upper limit	-21.2
Variability estimate	Standard error of the mean
Dispersion value	3.23

<b>Statistical analysis title</b>	Placebo vs PF--04950615 150 mg
-----------------------------------	--------------------------------

Statistical analysis description:

Week 52: LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group\*visit interaction, baseline value, baseline value\*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.

Comparison groups	Treatment Period: Placebo v Treatment Period: Bococizumab (PF--04950615) 150 mg
Number of subjects included in analysis	746
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	LS mean difference compared to placebo
Point estimate	-49.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-85.2
upper limit	-13.5
Variability estimate	Standard error of the mean
Dispersion value	18.27

### **Secondary: Percent Change From Baseline in Fasting High Density Lipoprotein Cholesterol (HDL-C) at Week 12, 24 and 52**

End point title	Percent Change From Baseline in Fasting High Density Lipoprotein Cholesterol (HDL-C) at Week 12, 24 and 52
-----------------	--

End point description:

FAS included all subjects who were randomized. Here, "n" signifies number of subjects who were evaluable at the specified time points.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week 12, 24, 52

End point values	Treatment Period: Placebo	Treatment Period: Bococizumab (PF--04950615) 150 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	247	499		
Units: percent change				
arithmetic mean (standard deviation)				
Week 12 (n =236, 469)	0.6 (± 13.93)	6.3 (± 13.86)		
Week 24 (n =237, 463)	0.6 (± 14.88)	6.3 (± 14.49)		
Week 52 (n =221, 425)	0.7 (± 14.24)	7.0 (± 15.60)		

## Statistical analyses

Statistical analysis title	Placebo vs PF--04950615 150 mg
Statistical analysis description:	
Week 12: LS mean difference and associated 95% CI and p-value were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.	
Comparison groups	Treatment Period: Placebo v Treatment Period: Bococizumab (PF--04950615) 150 mg
Number of subjects included in analysis	746
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	MMRM
Parameter estimate	LS mean difference compared to placebo
Point estimate	5.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	3.4
upper limit	7.6
Variability estimate	Standard error of the mean
Dispersion value	1.06

Statistical analysis title	Placebo vs PF--04950615 150 mg
Statistical analysis description:	
Week 24: LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.	
Comparison groups	Treatment Period: Placebo v Treatment Period: Bococizumab (PF--04950615) 150 mg

Number of subjects included in analysis	746
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	LS mean difference compared to placebo
Point estimate	5.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	3.2
upper limit	7.6
Variability estimate	Standard error of the mean
Dispersion value	1.14

<b>Statistical analysis title</b>	Placebo vs PF--04950615 150 mg
-----------------------------------	--------------------------------

Statistical analysis description:

Week 52: LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group\*visit interaction, baseline value, baseline value\*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.

Comparison groups	Treatment Period: Placebo v Treatment Period: Bococizumab (PF--04950615) 150 mg
Number of subjects included in analysis	746
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	LS mean difference compared to placebo
Point estimate	6
Confidence interval	
level	95 %
sides	2-sided
lower limit	3.6
upper limit	8.3
Variability estimate	Standard error of the mean
Dispersion value	1.2

### **Secondary: Percent Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) at Week 24 and 52: Treatment Period**

End point title	Percent Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) at Week 24 and 52: Treatment Period
-----------------	---

End point description:

FAS included all subjects who were randomized. Here, "n" signifies number of subjects who were evaluable at the specified time points.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week 24, 52

End point values	Treatment Period: Placebo	Treatment Period: Bococizumab (PF--04950615) 150 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	247	499		
Units: percent change				
arithmetic mean (standard deviation)				
Week 24 (n =236, 461)	-2.9 (± 21.72)	-47.5 (± 33.48)		
Week 52 (n =222, 425)	-4.7 (± 23.96)	-41.8 (± 32.67)		

## Statistical analyses

Statistical analysis title	Placebo vs PF--04950615 150 mg
Statistical analysis description:	
Week 24: LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.	
Comparison groups	Treatment Period: Placebo v Treatment Period: Bococizumab (PF--04950615) 150 mg
Number of subjects included in analysis	746
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	LS mean difference compared to placebo
Point estimate	-44.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-48.8
upper limit	-39.5
Variability estimate	Standard error of the mean
Dispersion value	2.39

Statistical analysis title	Placebo vs PF--04950615 150 mg
Statistical analysis description:	
Week 52: LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.	
Comparison groups	Treatment Period: Placebo v Treatment Period: Bococizumab (PF--04950615) 150 mg



Number of subjects included in analysis	746
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	LS mean difference compared to placebo
Point estimate	-36.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-40.9
upper limit	-31.4
Variability estimate	Standard error of the mean
Dispersion value	2.42

## Secondary: Percent Change From Baseline in Fasting Triglycerides (TG) at Week 12, 24 and 52

End point title	Percent Change From Baseline in Fasting Triglycerides (TG) at Week 12, 24 and 52
End point description: FAS included all subjects who were randomized. Here, "n" signifies number of subjects who were evaluable at the specified time points.	
End point type	Secondary
End point timeframe: Baseline, Week 12, 24, 52	

End point values	Treatment Period: Placebo	Treatment Period: Bococizumab (PF--04950615) 150 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	247	499		
Units: percent change				
arithmetic mean (standard deviation)				
Week 12 (n =236, 469)	-6.2 (± 32.92)	-16.2 (± 32.86)		
Week 24 (n =237, 463)	-8.9 (± 35.60)	-18.2 (± 65.13)		
Week 52 (n =221, 425)	-8.0 (± 41.46)	-15.8 (± 35.57)		

## Statistical analyses

Statistical analysis title	Placebo vs PF--04950615 150 mg
Statistical analysis description: Week 12: LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix	

was used.

Comparison groups	Treatment Period: Placebo v Treatment Period: Bococizumab (PF--04950615) 150 mg
Number of subjects included in analysis	746
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	LS mean difference compared to placebo
Point estimate	-10.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-15.1
upper limit	-5.1
Variability estimate	Standard error of the mean
Dispersion value	2.55

<b>Statistical analysis title</b>	Placebo vs PF--04950615 150 mg
Statistical analysis description: Week 24: LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.	
Comparison groups	Treatment Period: Placebo v Treatment Period: Bococizumab (PF--04950615) 150 mg
Number of subjects included in analysis	746
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	LS mean difference compared to placebo
Point estimate	-9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-17.9
upper limit	-0.2
Variability estimate	Standard error of the mean
Dispersion value	4.5

<b>Statistical analysis title</b>	Placebo vs PF--04950615 150 mg
Statistical analysis description: Week 52: LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.	
Comparison groups	Treatment Period: Placebo v Treatment Period: Bococizumab (PF--04950615) 150 mg

Number of subjects included in analysis	746
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	LS mean difference compared to placebo
Point estimate	-8.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-14.1
upper limit	-2.2
Variability estimate	Standard error of the mean
Dispersion value	3.04

## Secondary: Percent Change From Baseline in Fasting Apolipoprotein A-I (ApoA-I) at Week 12, 24 and 52

End point title	Percent Change From Baseline in Fasting Apolipoprotein A-I (ApoA-I) at Week 12, 24 and 52
End point description:	
FAS included all subjects who were randomized. Here, "n" signifies number of subjects who were evaluable at the specified time points.	
End point type	Secondary
End point timeframe:	
Baseline, Week 12, 24, 52	

End point values	Treatment Period: Placebo	Treatment Period: Bococizumab (PF--04950615) 150 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	247	499		
Units: percent change				
arithmetic mean (standard deviation)				
Week 12 (n =236, 468)	-0.9 (± 11.09)	3.4 (± 11.43)		
Week 24 (n =236, 461)	-1.6 (± 10.81)	2.5 (± 11.61)		
Week 52 (n =221, 425)	-1.0 (± 13.12)	3.4 (± 11.77)		

## Statistical analyses

Statistical analysis title	Placebo vs PF--04950615 150 mg
Statistical analysis description:	
Week 12: LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.	
Comparison groups	Treatment Period: Placebo v Treatment Period: Bococizumab

	(PF--04950615) 150 mg
Number of subjects included in analysis	746
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	LS mean difference compared to placebo
Point estimate	4.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.5
upper limit	5.8
Variability estimate	Standard error of the mean
Dispersion value	0.85

<b>Statistical analysis title</b>	Placebo vs PF--04950615 150 mg
Statistical analysis description:	
Week 24: LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.	
Comparison groups	Treatment Period: Placebo v Treatment Period: Bococizumab (PF--04950615) 150 mg
Number of subjects included in analysis	746
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	LS mean difference compared to placebo
Point estimate	3.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.2
upper limit	5.5
Variability estimate	Standard error of the mean
Dispersion value	0.86

<b>Statistical analysis title</b>	Placebo vs PF--04950615 150 mg
Statistical analysis description:	
Week 52: LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.	
Comparison groups	Treatment Period: Placebo v Treatment Period: Bococizumab (PF--04950615) 150 mg

Number of subjects included in analysis	746
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	LS mean difference compared to placebo
Point estimate	4.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.4
upper limit	6.2
Variability estimate	Standard error of the mean
Dispersion value	0.97

### Secondary: Percent Change From Baseline in Fasting Apolipoprotein A-II (ApoA-II) at Week 12, 24 and 52

End point title	Percent Change From Baseline in Fasting Apolipoprotein A-II (ApoA-II) at Week 12, 24 and 52
End point description:	
FAS included all subjects who were randomized. Here, "n" signifies number of subjects who were evaluable at the specified time points.	
End point type	Secondary
End point timeframe:	
Baseline, Week 12, 24, 52	

End point values	Treatment Period: Placebo	Treatment Period: Bococizumab (PF--04950615) 150 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	247	499		
Units: percent change				
arithmetic mean (standard deviation)				
Week 12 (n =235, 468)	2.0 (± 11.94)	3.0 (± 11.94)		
Week 24 (n =233, 462)	2.6 (± 12.12)	3.7 (± 14.12)		
Week 52 (n =220, 423)	0.7 (± 12.46)	1.9 (± 12.22)		

### Statistical analyses

Statistical analysis title	Placebo vs PF--04950615 150 mg
Statistical analysis description:	
Week 12: LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.	
Comparison groups	Treatment Period: Placebo v Treatment Period: Bococizumab

	(PF--04950615) 150 mg
Number of subjects included in analysis	746
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	LS mean difference compared to placebo
Point estimate	1.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.7
upper limit	2.8
Variability estimate	Standard error of the mean
Dispersion value	0.9

<b>Statistical analysis title</b>	Placebo vs PF--04950615 150 mg
Statistical analysis description:	
Week 52: LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.	
Comparison groups	Treatment Period: Placebo v Treatment Period: Bococizumab (PF--04950615) 150 mg
Number of subjects included in analysis	746
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	LS mean difference compared to placebo
Point estimate	0.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1
upper limit	2.7
Variability estimate	Standard error of the mean
Dispersion value	0.95

<b>Statistical analysis title</b>	Placebo vs PF--04950615 150 mg
Statistical analysis description:	
Week 24: LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.	
Comparison groups	Treatment Period: Placebo v Treatment Period: Bococizumab (PF--04950615) 150 mg

Number of subjects included in analysis	746
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	LS mean difference compared to placebo
Point estimate	0.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.1
upper limit	3
Variability estimate	Standard error of the mean
Dispersion value	1.04

### Secondary: Percent Change From Baseline in Fasting Very Low Density Lipoprotein Cholesterol (VLDL-C) at Week 12, 24 and 52

End point title	Percent Change From Baseline in Fasting Very Low Density Lipoprotein Cholesterol (VLDL-C) at Week 12, 24 and 52
End point description:	FAS included all subjects who were randomized. Here, "n" signifies number of subjects who were evaluable at the specified time points.
End point type	Secondary
End point timeframe:	Baseline, Week 12, 24, 52

End point values	Treatment Period: Placebo	Treatment Period: Bococizumab (PF--04950615) 150 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	247	499		
Units: percent change				
arithmetic mean (standard deviation)				
Week 12 (n =236, 469)	-6.2 (± 32.92)	-16.2 (± 32.86)		
Week 24 (n =237, 463)	-8.9 (± 35.60)	-18.2 (± 65.13)		
Week 52 (n =221, 425)	-8.0 (± 41.46)	-15.8 (± 35.57)		

### Statistical analyses

Statistical analysis title	Placebo vs PF--04950615 150 mg
Statistical analysis description:	Week 12: LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix

was used.

Comparison groups	Treatment Period: Placebo v Treatment Period: Bococizumab (PF--04950615) 150 mg
Number of subjects included in analysis	746
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	LS mean difference compared to placebo
Point estimate	-10.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-15.1
upper limit	-5.1
Variability estimate	Standard error of the mean
Dispersion value	2.55

<b>Statistical analysis title</b>	Placebo vs PF--04950615 150 mg
Statistical analysis description: Week 24: LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.	
Comparison groups	Treatment Period: Placebo v Treatment Period: Bococizumab (PF--04950615) 150 mg
Number of subjects included in analysis	746
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	LS mean difference compared to placebo
Point estimate	-9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-17.9
upper limit	-0.2
Variability estimate	Standard error of the mean
Dispersion value	4.5

<b>Statistical analysis title</b>	Placebo vs PF--04950615 150 mg
Statistical analysis description: Week 52: LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.	
Comparison groups	Treatment Period: Placebo v Treatment Period: Bococizumab (PF--04950615) 150 mg



Number of subjects included in analysis	746
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	LS mean difference compared to placebo
Point estimate	-8.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-14.1
upper limit	-2.2
Variability estimate	Standard error of the mean
Dispersion value	3.04

### Secondary: Absolute Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) by Triglycerides Cut-off of Less Than (<) 200 Milligram per Deciliter (mg/dL) at Week 12

End point title	Absolute Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) by Triglycerides Cut-off of Less Than (<) 200 Milligram per Deciliter (mg/dL) at Week 12
End point description:	A subset of FAS included all participants who were randomized and had TG <200 mg/dL at pre-randomization. Here, "n" signifies number of subjects who were evaluable at the specified time points.
End point type	Secondary
End point timeframe:	
Baseline, Week 12	

End point values	Treatment Period: Placebo	Treatment Period: Bococizumab (PF--04950615) 150 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	164	331		
Units: mg/dL				
arithmetic mean (standard deviation)				
Baseline (n =164, 331)	130.1 (± 25.22)	130.2 (± 28.72)		
Change at Week 12 (n =158, 313)	-0.5 (± 22.37)	-67.3 (± 40.14)		

### Statistical analyses

Statistical analysis title	Placebo vs PF--04950615 150 mg
Statistical analysis description:	
LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction and geographical region. An unstructured variance covariance matrix was used.	

Comparison groups	Treatment Period: Placebo v Treatment Period: Bococizumab (PF--04950615) 150 mg
Number of subjects included in analysis	495
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	LS mean difference compared to placebo
Point estimate	-66.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-73
upper limit	-60.5
Variability estimate	Standard error of the mean
Dispersion value	3.18

**Secondary: Absolute Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) by Triglycerides Cut-off of Greater Than or Equal to ( $\geq$ ) 200 Milligram per Deciliter (mg/dL) at Week 12**

End point title	Absolute Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) by Triglycerides Cut-off of Greater Than or Equal to ( $\geq$ ) 200 Milligram per Deciliter (mg/dL) at Week 12
End point description:	A subset of FAS included all participants who were randomized and had TG $\geq$ 200 mg/dL at pre-randomization. Here, "n" signifies number of subjects who were evaluable at the specified time points.
End point type	Secondary
End point timeframe:	
Baseline, Week 12	

End point values	Treatment Period: Placebo	Treatment Period: Bococizumab (PF--04950615) 150 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	83	168		
Units: mg/dL				
arithmetic mean (standard deviation)				
Baseline (n =83, 168)	143.7 ( $\pm$ 35.49)	147.2 ( $\pm$ 39.48)		
Change at Week 12 (n =77, 155)	-6.6 ( $\pm$ 29.61)	-74.1 ( $\pm$ 48.04)		

**Statistical analyses**

Statistical analysis title	Placebo vs PF--04950615 150 mg
----------------------------	--------------------------------

**Statistical analysis description:**

LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group\*visit interaction, baseline value, baseline value\*visit interaction and geographical region. An unstructured variance covariance matrix was used.

Comparison groups	Treatment Period: Placebo v Treatment Period: Bococizumab (PF--04950615) 150 mg
Number of subjects included in analysis	251
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	LS mean difference compared to placebo
Point estimate	-66.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-76.7
upper limit	-55.4
Variability estimate	Standard error of the mean
Dispersion value	5.4

### **Secondary: Absolute Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) at Week 12**

End point title	Absolute Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) at Week 12
End point description:	
FAS included all subjects who were randomized. Here, "n" signifies number of subjects who were evaluable at the specified time points.	
End point type	Secondary
End point timeframe:	
Baseline, Week 12	

<b>End point values</b>	Treatment Period: Placebo	Treatment Period: Bococizumab (PF--04950615) 150 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	247	499		
Units: mg/dL				
arithmetic mean (standard deviation)				
Baseline (n =247, 499)	134.7 (± 29.71)	135.9 (± 33.67)		
Change at Week 12 (n =235, 468)	-2.5 (± 25.07)	-69.6 (± 42.98)		

**Statistical analyses**

<b>Statistical analysis title</b>	Placebo vs PF--04950615 150 mg
Statistical analysis description: LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.	
Comparison groups	Treatment Period: Placebo v Treatment Period: Bococizumab (PF--04950615) 150 mg
Number of subjects included in analysis	746
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	LS mean difference compared to placebo
Point estimate	-66.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-72
upper limit	-61.1
Variability estimate	Standard error of the mean
Dispersion value	2.77

## Secondary: Absolute Change From Baseline in Fasting Total Cholesterol (TC) at Week 12

End point title	Absolute Change From Baseline in Fasting Total Cholesterol (TC) at Week 12
End point description: FAS included all subjects who were randomized. Here, "n" signifies number of subjects who were evaluable at the specified time points	
End point type	Secondary
End point timeframe: Baseline, Week 12	

End point values	Treatment Period: Placebo	Treatment Period: Bococizumab (PF--04950615) 150 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	247	499		
Units: mg/dL				
arithmetic mean (standard deviation)				
Baseline (n =247, 499)	209.4 (± 33.84)	210.3 (± 37.97)		
Change at Week 12 (n =236, 469)	-5.9 (± 29.61)	-75.4 (± 46.91)		

## Statistical analyses

<b>Statistical analysis title</b>	Placebo vs PF--04950615 150 mg
Statistical analysis description: LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.	
Comparison groups	Treatment Period: Placebo v Treatment Period: Bococizumab (PF--04950615) 150 mg
Number of subjects included in analysis	746
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	LS mean difference compared to placebo
Point estimate	-69.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-75.2
upper limit	-63.1
Variability estimate	Standard error of the mean
Dispersion value	3.08

### Secondary: Absolute Change From Baseline in Fasting Non High Density Lipoprotein Cholesterol (non HDL-C) at Week 12

End point title	Absolute Change From Baseline in Fasting Non High Density Lipoprotein Cholesterol (non HDL-C) at Week 12
End point description: FAS included all subjects who were randomized. Here, "n" signifies number of subjects who were evaluable at the specified time points.	
End point type	Secondary
End point timeframe: Baseline, Week 12	

End point values	Treatment Period: Placebo	Treatment Period: Bococizumab (PF--04950615) 150 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	247	499		
Units: mg/dL				
arithmetic mean (standard deviation)				
Baseline (n =247, 499)	160.2 (± 33.49)	162.1 (± 37.78)		
Change at Week 12 (n =236, 469)	-5.8 (± 29.59)	-77.9 (± 48.28)		

### Statistical analyses

<b>Statistical analysis title</b>	Placebo vs PF--04950615 150 mg
Statistical analysis description: LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.	
Comparison groups	Treatment Period: Placebo v Treatment Period: Bococizumab (PF--04950615) 150 mg
Number of subjects included in analysis	746
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	LS mean difference compared to placebo
Point estimate	-71.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-77.5
upper limit	-65.1
Variability estimate	Standard error of the mean
Dispersion value	3.14

## Secondary: Absolute Change From Baseline in Fasting Apolipoprotein B (ApoB) at Week 12

End point title	Absolute Change From Baseline in Fasting Apolipoprotein B (ApoB) at Week 12
End point description: FAS included all subjects who were randomized. Here, "n" signifies number of subjects who were evaluable at the specified time points.	
End point type	Secondary
End point timeframe: Baseline, Week 12	

End point values	Treatment Period: Placebo	Treatment Period: Bococizumab (PF--04950615) 150 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	247	499		
Units: mg/dL				
arithmetic mean (standard deviation)				
Baseline (n =247, 499)	106.1 (± 20.43)	107.1 (± 23.33)		
Change at Week 12 (n =234, 467)	-1.6 (± 18.09)	-49.8 (± 31.81)		

## Statistical analyses

<b>Statistical analysis title</b>	Placebo vs PF--04950615 150 mg
Statistical analysis description: LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.	
Comparison groups	Treatment Period: Placebo v Treatment Period: Bococizumab (PF--04950615) 150 mg
Number of subjects included in analysis	746
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	LS mean difference compared to placebo
Point estimate	-47.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-51.9
upper limit	-43.6
Variability estimate	Standard error of the mean
Dispersion value	2.12

## Secondary: Absolute Change From Baseline in Fasting Lipoprotein (A) (Lp[A]) at Week 12

End point title	Absolute Change From Baseline in Fasting Lipoprotein (A) (Lp[A]) at Week 12
End point description: FAS included all subjects who were randomized. Here, "n" signifies number of subjects who were evaluable at the specified time points.	
End point type	Secondary
End point timeframe: Baseline, Week 12	

End point values	Treatment Period: Placebo	Treatment Period: Bococizumab (PF--04950615) 150 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	247	499		
Units: mg/dL				
arithmetic mean (standard deviation)				
Baseline (n =247, 499)	48.5 (± 54.04)	47.3 (± 53.55)		
Change at Week 12 (n =235, 469)	0.1 (± 10.91)	-10.3 (± 17.01)		

## Statistical analyses

<b>Statistical analysis title</b>	Placebo vs PF--04950615 150 mg
Statistical analysis description: LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.	
Comparison groups	Treatment Period: Placebo v Treatment Period: Bococizumab (PF--04950615) 150 mg
Number of subjects included in analysis	746
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	LS mean difference compared to placebo
Point estimate	-10.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-12.5
upper limit	-8.3
Variability estimate	Standard error of the mean
Dispersion value	1.06

## Secondary: Absolute Change From Baseline in Fasting High Density Lipoprotein Cholesterol (HDL-C) at Week 12

End point title	Absolute Change From Baseline in Fasting High Density Lipoprotein Cholesterol (HDL-C) at Week 12
End point description: FAS included all subjects who were randomized. Here, "n" signifies number of subjects who were evaluable at the specified time points.	
End point type	Secondary
End point timeframe: Baseline, Week 12	

End point values	Treatment Period: Placebo	Treatment Period: Bococizumab (PF--04950615) 150 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	247	499		
Units: mg/dL				
arithmetic mean (standard deviation)				
Baseline (n =247, 499)	49.2 (± 13.20)	48.3 (± 11.60)		
Change at Week 12 (n =236, 469)	-0.1 (± 6.75)	2.5 (± 6.64)		

## Statistical analyses



<b>Statistical analysis title</b>	Placebo vs PF--04950615 150 mg
Statistical analysis description: LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.	
Comparison groups	Treatment Period: Placebo v Treatment Period: Bococizumab (PF--04950615) 150 mg
Number of subjects included in analysis	746
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	LS mean difference compared to placebo
Point estimate	2.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.6
upper limit	3.6
Variability estimate	Standard error of the mean
Dispersion value	0.52

**Secondary: Absolute Change From Baseline in Ratio of Fasting Total Cholesterol (TC) to High Density Lipoprotein Cholesterol (HDL-C) at Week 12, 24 and 52**

End point title	Absolute Change From Baseline in Ratio of Fasting Total Cholesterol (TC) to High Density Lipoprotein Cholesterol (HDL-C) at Week 12, 24 and 52
-----------------	--

End point description:

FAS included all subjects who were randomized. Here, "n" signifies number of subjects who were evaluable at the specified time points.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week 12, 24, 52

<b>End point values</b>	Treatment Period: Placebo	Treatment Period: Bococizumab (PF--04950615) 150 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	247	499		
Units: ratio				
arithmetic mean (standard deviation)				
Baseline (n =247, 499)	4.6 (± 1.90)	4.6 (± 1.31)		
Change at Week 12 (n =236, 469)	-0.2 (± 1.27)	-1.8 (± 1.29)		
Change at Week 24 (n =237, 463)	-0.2 (± 1.42)	-1.6 (± 1.38)		
Change at Week 52 (n =221, 425)	-0.2 (± 1.62)	-1.5 (± 1.32)		

## Statistical analyses

Statistical analysis title	Placebo vs PF--04950615 150 mg
Statistical analysis description:	
Week 12: LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.	
Comparison groups	Treatment Period: Placebo v Treatment Period: Bococizumab (PF--04950615) 150 mg
Number of subjects included in analysis	746
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	LS mean difference compared to placebo
Point estimate	-1.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.8
upper limit	-1.5
Variability estimate	Standard error of the mean
Dispersion value	0.08

Statistical analysis title	Placebo vs PF--04950615 150 mg
Statistical analysis description:	
Week 24: LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.	
Comparison groups	Treatment Period: Placebo v Treatment Period: Bococizumab (PF--04950615) 150 mg
Number of subjects included in analysis	746
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	LS mean difference compared to placebo
Point estimate	-1.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.6
upper limit	-1.3
Variability estimate	Standard error of the mean
Dispersion value	0.1

Statistical analysis title	Placebo vs PF--04950615 150 mg
Statistical analysis description:	
Week 52: LS mean difference and associated 95% CI were derived from MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.	

Comparison groups	Treatment Period: Placebo v Treatment Period: Bococizumab (PF--04950615) 150 mg
Number of subjects included in analysis	746
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	LS mean difference compared to placebo
Point estimate	-1.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.6
upper limit	-1.2
Variability estimate	Standard error of the mean
Dispersion value	0.12

### Secondary: Absolute Change From Baseline in Ratio of Fasting Apolipoprotein B (ApoB) to Apolipoprotein A-I (ApoA-I) at Week 12, 24 and 52

End point title	Absolute Change From Baseline in Ratio of Fasting Apolipoprotein B (ApoB) to Apolipoprotein A-I (ApoA-I) at Week 12, 24 and 52
End point description:	FAS included all subjects who were randomized. Here, "n" signifies number of subjects who were evaluable at the specified time points.
End point type	Secondary
End point timeframe:	Baseline, Week 12, 24, 52

End point values	Treatment Period: Placebo	Treatment Period: Bococizumab (PF--04950615) 150 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	247	499		
Units: ratio				
arithmetic mean (standard deviation)				
Baseline (n =247, 499)	0.7 (± 0.25)	0.8 (± 0.22)		
Change at Week 12 (n =234, 467)	0.0 (± 0.14)	-0.4 (± 0.25)		
Change at Week 24 (n =236, 461)	-0.0 (± 0.16)	-0.3 (± 0.27)		
Change at Week 52 (n =221, 425)	0.0 (± 0.66)	-0.3 (± 0.25)		

### Statistical analyses

Statistical analysis title	Placebo vs PF--04950615 150 mg
----------------------------	--------------------------------

Statistical analysis description:

Week 12: LS mean difference and associated 95% confidence interval CI were derived from an MMRM

model with fixed effects for treatment group, visit, treatment group\*visit interaction, baseline value, baseline value\*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.

Comparison groups	Treatment Period: Placebo v Treatment Period: Bococizumab (PF--04950615) 150 mg
Number of subjects included in analysis	746
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	LS mean difference compared to placebo
Point estimate	-0.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.4
upper limit	-0.3
Variability estimate	Standard error of the mean
Dispersion value	0.02

<b>Statistical analysis title</b>	Placebo vs PF--04950615 150 mg
-----------------------------------	--------------------------------

Statistical analysis description:

Week 24: LS mean difference and associated 95% confidence interval CI were derived from an MMRM model with fixed effects for treatment group, visit, treatment group\*visit interaction, baseline value, baseline value\*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.

Comparison groups	Treatment Period: Placebo v Treatment Period: Bococizumab (PF--04950615) 150 mg
Number of subjects included in analysis	746
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	LS mean difference compared to placebo
Point estimate	-0.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.3
upper limit	-0.3
Variability estimate	Standard error of the mean
Dispersion value	0.02

<b>Statistical analysis title</b>	Placebo vs PF--04950615 150 mg
-----------------------------------	--------------------------------

Statistical analysis description:

Week 52: LS mean difference and associated 95% confidence interval CI were derived from an MMRM model with fixed effects for treatment group, visit, treatment group\*visit interaction, baseline value, baseline value\*visit interaction, geographical region and triglyceride subgroup. An unstructured variance covariance matrix was used.

Comparison groups	Treatment Period: Placebo v Treatment Period: Bococizumab (PF--04950615) 150 mg
-------------------	---

Number of subjects included in analysis	746
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	LS mean difference compared to placebo
Point estimate	-0.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.4
upper limit	-0.2
Variability estimate	Standard error of the mean
Dispersion value	0.04

### Secondary: Percentage of Subjects Achieving Fasting Low Density Lipoprotein Cholesterol (LDL-C) Less Than or Equal to ( $\leq$ ) 100 Milligram per Deciliter (mg/dL) at Week 12, 24 and 52

End point title	Percentage of Subjects Achieving Fasting Low Density Lipoprotein Cholesterol (LDL-C) Less Than or Equal to ( $\leq$ ) 100 Milligram per Deciliter (mg/dL) at Week 12, 24 and 52
End point description:	FAS included all subjects who were randomized. Here, "n" signifies number of subjects who were evaluable at the specified time points.
End point type	Secondary
End point timeframe:	Week 12, 24, 52

End point values	Treatment Period: Placebo	Treatment Period: Bococizumab (PF--04950615) 150 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	247	499		
Units: percentage of subjects				
number (not applicable)				
Week 12 (n =235, 468)	10.2	81.6		
Week 24 (n =236, 461)	19.9	75.1		
Week 52 (n =222, 425)	25.2	72.7		

### Statistical analyses

Statistical analysis title	Placebo vs PF--04950615 150 mg
Statistical analysis description:	Week 12: Odds ratio, associated 95% CI were derived from a logistic regression model with fixed effects for treatment group, baseline value, geographical region and triglyceride subgroup.
Comparison groups	Treatment Period: Placebo v Treatment Period: Bococizumab

	(PF--04950615) 150 mg
Number of subjects included in analysis	746
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Odds ratio (OR)
Point estimate	53.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	32.08
upper limit	90.59

<b>Statistical analysis title</b>	Placebo vs PF--04950615 150 mg
Statistical analysis description:	
Week 24: Odds ratio, associated 95% CI were derived from a logistic regression model with fixed effects for treatment group, baseline value, geographical region and triglyceride subgroup.	
Comparison groups	Treatment Period: Placebo v Treatment Period: Bococizumab (PF--04950615) 150 mg
Number of subjects included in analysis	746
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Odds ratio (OR)
Point estimate	17
Confidence interval	
level	95 %
sides	2-sided
lower limit	11.15
upper limit	26.07

<b>Statistical analysis title</b>	Placebo vs PF--04950615 150 mg
Statistical analysis description:	
Week 52: Odds ratio, associated 95% CI were derived from a logistic regression model with fixed effects for treatment group, baseline value, geographical region and triglyceride subgroup.	
Comparison groups	Treatment Period: Placebo v Treatment Period: Bococizumab (PF--04950615) 150 mg
Number of subjects included in analysis	746
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Odds ratio (OR)
Point estimate	9.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	6.18
upper limit	13.48

**Secondary: Percentage of Subjects Achieving Fasting Low Density Lipoprotein Cholesterol (LDL-C) Less Than or Equal to ( $\leq$ ) 70 Milligram per Deciliter (mg/dL) at Week 12, 24 and 52**

End point title	Percentage of Subjects Achieving Fasting Low Density Lipoprotein Cholesterol (LDL-C) Less Than or Equal to ( $\leq$ ) 70 Milligram per Deciliter (mg/dL) at Week 12, 24 and 52
-----------------	--

End point description:

FAS included all subjects who were randomized. Here, "n" signifies number of subjects who were evaluable at the specified time points.

End point type	Secondary
----------------	-----------

End point timeframe:

Week 12, 24, 52

End point values	Treatment Period: Placebo	Treatment Period: Bococizumab (PF--04950615) 150 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	247	499		
Units: percentage of subjects				
number (not applicable)				
Week 12 (n =235, 468)	1.3	62.2		
Week 24 (n =236, 461)	1.7	60.1		
Week 52 (n 222, 425)	3.2	53.4		

**Statistical analyses**

<b>Statistical analysis title</b>	Placebo vs PF--04950615 150 mg
-----------------------------------	--------------------------------

Statistical analysis description:

Week 12: Odds ratio, associated 95% CI were derived from a logistic regression model with fixed effects for treatment group, baseline value, geographical region and triglyceride subgroup.

Comparison groups	Treatment Period: Placebo v Treatment Period: Bococizumab (PF--04950615) 150 mg
Number of subjects included in analysis	746
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Odds ratio (OR)
Point estimate	156.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	48.84
upper limit	501.11

<b>Statistical analysis title</b>	Placebo vs PF--04950615 150 mg
Statistical analysis description:	
Week 24: Odds ratio, associated 95% CI were derived from a logistic regression model with fixed effects for treatment group, baseline value, geographical region and triglyceride subgroup.	
Comparison groups	Treatment Period: Placebo v Treatment Period: Bococizumab (PF--04950615) 150 mg
Number of subjects included in analysis	746
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Odds ratio (OR)
Point estimate	110.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	39.77
upper limit	308.46

<b>Statistical analysis title</b>	Placebo vs PF--04950615 150 mg
Statistical analysis description:	
Week 52: Odds ratio, associated 95% CI were derived from a logistic regression model with fixed effects for treatment group, baseline value, geographical region and triglyceride subgroup.	
Comparison groups	Treatment Period: Placebo v Treatment Period: Bococizumab (PF--04950615) 150 mg
Number of subjects included in analysis	746
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Odds ratio (OR)
Point estimate	43.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	19.52
upper limit	96.13

<b>Secondary: Plasma Concentration Versus Time Summary of PF-04950615</b>	
End point title	Plasma Concentration Versus Time Summary of PF-04950615 <sup>[1]</sup>
End point description:	
Analysis set included all subjects who had taken at least 1 dose of Bococizumab (PF--04950615) 150 mg. Here, "n" signifies number of subjects who were evaluable at the specified time points.	
End point type	Secondary
End point timeframe:	
Week 12, 24, 52	



Notes:

[1] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.  
Justification: The endpoint was planned to be analyzed for Bococizumab 150 mg arm (treatment period) only.

<b>End point values</b>	Treatment Period: Bococizumab (PF--04950615) 150 mg			
Subject group type	Reporting group			
Number of subjects analysed	499			
Units: microgram per milliliter				
geometric mean (standard deviation)				
Week 12 (n =456)	5.37 (± 5.327)			
Week 24 (n =448)	5.28 (± 5.888)			
Week 52 (n =418)	4.01 (± 4.652)			

### Statistical analyses

No statistical analyses for this end point

### Secondary: Percentage of Subjects With Adverse Events (AEs) Related to Type 1 and 3 Hypersensitivity Reactions and Injection Site Reactions

End point title	Percentage of Subjects With Adverse Events (AEs) Related to Type 1 and 3 Hypersensitivity Reactions and Injection Site Reactions
-----------------	--

End point description:

Type 1 hypersensitivity or allergic reactions were possible in response to any injected protein and included shortness of breath, urticaria, anaphylaxis and angioedema. Type 3 hypersensitivity reactions were similar to Type 1 hypersensitivity reactions but were likely to be delayed from the time of injection and included symptoms such as rash, urticaria, polyarthritis, myalgia's, polysynovitis, fever and if severe then included glomerulonephritis. Injection site reactions included injection site bruising, discolouration, erythema, haematoma, haemorrhage, nodule, induration, inflammation, mass, pain, paraesthesia, pruritus, swelling, vesicles, warmth, scab and rash. Subjects with type 1 or type 3 hypersensitivity reactions and subjects with injection site reactions were reported in this endpoint.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline up to end of study (up to 110 weeks)

<b>End point values</b>	Treatment Period: Placebo	Treatment Period: Bococizumab (PF--04950615) 150 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	247	499		
Units: percentage of subjects				
number (not applicable)				

With type 1 or 3 hypersensitivity reactions	0.0	0.2		
With injection site reactions	0.8	13.4		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Percentage of Subjects With Anti-Drug Antibodies (ADA) and Neutralizing Antibodies (nAb): Treatment Period

End point title	Percentage of Subjects With Anti-Drug Antibodies (ADA) and Neutralizing Antibodies (nAb): Treatment Period <sup>[2]</sup>
-----------------	---

End point description:

Percentage of subjects with at least 1 positive ADA titer or 1 positive nAb titer were reported. ADA titer  $\geq 6.23$  (log 2) unit was considered to be ADA positive and nAb titer  $\geq 1.58$  (log 2) unit was considered to be nAb positive. Analysis set included all participants who received at least 1 dose of PF-04950615 150 mg. This endpoint was planned not to be analysed for placebo reporting arm. Here, "N" signifies number of subjects who were evaluable for this endpoint.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline up to Week 58

Notes:

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint was planned to be analyzed for Bococizumab 150 mg arm (treatment period) only.

<b>End point values</b>	Treatment Period: Bococizumab (PF--04950615) 150 mg			
Subject group type	Reporting group			
Number of subjects analysed	491			
Units: Percentage of subjects				
number (not applicable)				
Baseline up to Week 58: ADA positive	54.8			
Baseline up to Week 58: nAb positive	37.9			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Percentage of Subjects With Anti-Drug Antibodies (ADA) and Neutralizing Antibodies (nAb): Extension Period

End point title	Percentage of Subjects With Anti-Drug Antibodies (ADA) and Neutralizing Antibodies (nAb): Extension Period
-----------------	--

End point description:

Percentage of subjects with at least 1 positive ADA titer or 1 positive nAb titer were reported. ADA titer  $\geq 6.23$  (log2) unit was considered to be ADA positive and nAb titer  $\geq 1.58$  (log2) unit was considered

to be nAb positive. All subjects who consented for extension period. This endpoint was planned not to be analyzed for reporting arms Placebo (Extension period) and Bococizumab ADA negative (Extension period). Here, "n" signifies number of participants who were evaluable at specified time points.

End point type	Secondary
End point timeframe:	
Week 58 (follow-up), Week 71, Week 84, Week 97, Week 110	

End point values	Extension Period: Bococizumab ADA positive			
Subject group type	Reporting group			
Number of subjects analysed	33			
Units: percentage of subjects				
number (not applicable)				
Week 58 (follow up): ADA positive (n =33)	100.0			
Week 58 (follow up): nAB positive (n =33)	60.6			
Week 71: ADA positive (n =31)	87.1			
Week 71: nAb positive (n =31)	35.5			
Week 84: ADA positive (n =28)	82.1			
Week 84: nAb positive (n =28)	25.0			
Week 97: ADA positive (n =22)	86.4			
Week 97: nAb positive (n =22)	18.2			
Week 110: ADA positive (n =17)	100.0			
Week 110: nAb positive (n =17)	11.8			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Subjects Who Changed Concomitant Medication During Extension Period

End point title	Number of Subjects Who Changed Concomitant Medication During Extension Period
End point description:	
In this endpoint, total number of subjects who changed their lipid-lowering medications or added a monoclonal antibody medication during the extension period were reported. All subjects who consented for extension period.	
End point type	Secondary
End point timeframe:	
Week 58 follow-up to Week 110	

<b>End point values</b>	Extension Period: Placebo	Extension Period: Bococizumab ADA positive	Extension Period: Bococizumab ADA negative	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	44	33	56	
Units: subjects	2	4	3	

### Statistical analyses

No statistical analyses for this end point

### Secondary: Percent Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) at Week 58 (follow up), 71, 84, 97 and 110: Extension Period

End point title	Percent Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) at Week 58 (follow up), 71, 84, 97 and 110: Extension Period
-----------------	--

End point description:

All subject who consented for extension period. This endpoint was planned not to be analyzed for reporting arms: Placebo (Extension Period) and Bococizumab ADA negative (Extension Period).

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week 58 (follow up), 71, 84, 97, 110

<b>End point values</b>	Extension Period: Bococizumab ADA positive			
Subject group type	Reporting group			
Number of subjects analysed	33			
Units: percent change				
arithmetic mean (standard deviation)				
Week 58 (follow up)	6.7 (± 27.70)			
Week 71	8.7 (± 34.83)			
Week 84	7.0 (± 30.34)			
Week 97	2.6 (± 31.43)			
Week 110	15.5 (± 36.17)			

### Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

For SAEs: Baseline up to Week 110 and for other AEs: Baseline up to Week 58

Adverse event reporting additional description:

Event may be serious in 1 and nonserious in other subject or 1 subject may have experienced both serious and nonserious AE. Subjects evaluable:treatment period: subjects who received at least 1 dose of study drug;extension period:subjects who consented for extension period.Nonserious AEs were not collected for extension period.99999=not available.

Assessment type	Non-systematic
-----------------	----------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	19.0
--------------------	------

### Reporting groups

Reporting group title	Placebo
-----------------------	---------

Reporting group description:

Subjects received placebo matched to Bococizumab (PF-04950615) subcutaneous injection once every 2 weeks up to Week 52. Subjects were followed up to Week 58.

Reporting group title	Bococizumab (PF--04950615) 150 mg
-----------------------	-----------------------------------

Reporting group description:

Subjects received Bococizumab (PF-04950615) 150 mg subcutaneous injection once every 2 weeks up to Week 52. Subjects were followed up to Week 58.

Reporting group title	Extension Period: Placebo
-----------------------	---------------------------

Reporting group description:

Subjects randomized to Placebo arm in treatment period and consented for extension period after Week 58 follow-up visit, were followed for SAEs and concomitant medications up to Week 110.

Reporting group title	Extension Period: Bococizumab ADA positive
-----------------------	--

Reporting group description:

Subjects randomized to Bococizumab in treatment period were classified as either ADA positive or ADA negative based on their ADA assessment at Week 58 follow-up visit. In extension period, subjects who were ADA positive and consented for extension period were assessed for ADA and LDL-C direct measurement until ADA titers were no longer detectable or had returned to baseline titer (less than or equal to 1.58 log2 units above a positive baseline titer) or until Week 110 along with SAEs and concomitant medication, from Week 58 follow up visit to Week 110.

Reporting group title	Extension Period: Bococizumab ADA negative
-----------------------	--

Reporting group description:

Subjects randomized to Bococizumab in treatment period were classified as either ADA positive or ADA negative based on their Week 58 follow-up ADA assessment. Subjects who were ADA negative and consented for extension period were followed for SAEs and concomitant medication, from Week 58 follow up visit to Week 110.

Serious adverse events	Placebo	Bococizumab (PF--04950615) 150 mg	Extension Period: Placebo
Total subjects affected by serious adverse events			
subjects affected / exposed	32 / 247 (12.96%)	44 / 499 (8.82%)	2 / 44 (4.55%)
number of deaths (all causes)	2	2	0
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			

Adenocarcinoma of colon			
subjects affected / exposed	1 / 247 (0.40%)	0 / 499 (0.00%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bone cancer			
subjects affected / exposed	1 / 247 (0.40%)	0 / 499 (0.00%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Breast cancer			
subjects affected / exposed	1 / 247 (0.40%)	0 / 499 (0.00%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Breast cancer recurrent			
subjects affected / exposed	1 / 247 (0.40%)	0 / 499 (0.00%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malignant melanoma			
subjects affected / exposed	0 / 247 (0.00%)	1 / 499 (0.20%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Non-small cell lung cancer			
subjects affected / exposed	1 / 247 (0.40%)	1 / 499 (0.20%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Plasma cell myeloma			
subjects affected / exposed	0 / 247 (0.00%)	1 / 499 (0.20%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin cancer			
subjects affected / exposed	1 / 247 (0.40%)	0 / 499 (0.00%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tonsil cancer			

subjects affected / exposed	0 / 247 (0.00%)	1 / 499 (0.20%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Disease progression			
alternative dictionary used: MedDRA v20.0J			
subjects affected / exposed	0 / 247 (0.00%)	0 / 499 (0.00%)	1 / 44 (2.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Aortic aneurysm			
subjects affected / exposed	1 / 247 (0.40%)	0 / 499 (0.00%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral artery dissection			
subjects affected / exposed	1 / 247 (0.40%)	0 / 499 (0.00%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
POSSIBLE SEIZURE DISORDER SECONDARY TO AMPHETAMINE ABUSE			
subjects affected / exposed	1 / 247 (0.40%)	0 / 499 (0.00%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Asthenia			
subjects affected / exposed	1 / 247 (0.40%)	0 / 499 (0.00%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chest pain			
subjects affected / exposed	1 / 247 (0.40%)	1 / 499 (0.20%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Complication associated with device			

subjects affected / exposed	0 / 247 (0.00%)	1 / 499 (0.20%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Death			
subjects affected / exposed	1 / 247 (0.40%)	1 / 499 (0.20%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Non-cardiac chest pain			
subjects affected / exposed	0 / 247 (0.00%)	5 / 499 (1.00%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 5	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	1 / 247 (0.40%)	0 / 499 (0.00%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular stent occlusion			
subjects affected / exposed	0 / 247 (0.00%)	1 / 499 (0.20%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Acute respiratory distress syndrome			
subjects affected / exposed	1 / 247 (0.40%)	0 / 499 (0.00%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Asthma			
subjects affected / exposed	1 / 247 (0.40%)	0 / 499 (0.00%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 247 (0.00%)	2 / 499 (0.40%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 4	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemoptysis			



subjects affected / exposed	0 / 247 (0.00%)	1 / 499 (0.20%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	0 / 247 (0.00%)	1 / 499 (0.20%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary hypertension			
subjects affected / exposed	1 / 247 (0.40%)	0 / 499 (0.00%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chest pain			
alternative dictionary used: MedDRA v20.0J			
subjects affected / exposed	0 / 247 (0.00%)	0 / 499 (0.00%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspnoea			
alternative dictionary used: MedDRA v 20.0J			
subjects affected / exposed	0 / 247 (0.00%)	0 / 499 (0.00%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Depression			
subjects affected / exposed	0 / 247 (0.00%)	1 / 499 (0.20%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Depression suicidal			
subjects affected / exposed	0 / 247 (0.00%)	1 / 499 (0.20%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Paranoia			

subjects affected / exposed	0 / 247 (0.00%)	1 / 499 (0.20%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric decompensation			
subjects affected / exposed	0 / 247 (0.00%)	1 / 499 (0.20%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Suicidal behaviour			
subjects affected / exposed	1 / 247 (0.40%)	0 / 499 (0.00%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Gamma-glutamyltransferase increased			
subjects affected / exposed	1 / 247 (0.40%)	0 / 499 (0.00%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Arterial injury			
subjects affected / exposed	1 / 247 (0.40%)	0 / 499 (0.00%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Acute myocardial infarction			
subjects affected / exposed	2 / 247 (0.81%)	0 / 499 (0.00%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Angina pectoris			
subjects affected / exposed	1 / 247 (0.40%)	3 / 499 (0.60%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Angina unstable			

subjects affected / exposed	2 / 247 (0.81%)	4 / 499 (0.80%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 4	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arrhythmia			
subjects affected / exposed	1 / 247 (0.40%)	0 / 499 (0.00%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial fibrillation			
subjects affected / exposed	0 / 247 (0.00%)	2 / 499 (0.40%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure			
subjects affected / exposed	2 / 247 (0.81%)	0 / 499 (0.00%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coronary artery disease			
subjects affected / exposed	0 / 247 (0.00%)	1 / 499 (0.20%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coronary artery occlusion			
subjects affected / exposed	0 / 247 (0.00%)	1 / 499 (0.20%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Left ventricular failure			
subjects affected / exposed	0 / 247 (0.00%)	1 / 499 (0.20%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocardial infarction			
subjects affected / exposed	3 / 247 (1.21%)	0 / 499 (0.00%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Sinus bradycardia			

subjects affected / exposed	1 / 247 (0.40%)	0 / 499 (0.00%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sinus node dysfunction			
subjects affected / exposed	0 / 247 (0.00%)	1 / 499 (0.20%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ventricular tachycardia			
subjects affected / exposed	0 / 247 (0.00%)	1 / 499 (0.20%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial fibrillation1			
alternative dictionary used: MedDRA 20.0J			
subjects affected / exposed	0 / 247 (0.00%)	0 / 499 (0.00%)	1 / 44 (2.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocardial ischaemia			
alternative dictionary used: MedDRA 20.0J			
subjects affected / exposed	0 / 247 (0.00%)	0 / 499 (0.00%)	1 / 44 (2.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Cerebral haematoma			
subjects affected / exposed	0 / 247 (0.00%)	1 / 499 (0.20%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebral haemorrhage			
subjects affected / exposed	0 / 247 (0.00%)	1 / 499 (0.20%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebrovascular accident			

subjects affected / exposed	0 / 247 (0.00%)	3 / 499 (0.60%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ischaemic stroke			
subjects affected / exposed	0 / 247 (0.00%)	1 / 499 (0.20%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Miller Fisher syndrome			
subjects affected / exposed	0 / 247 (0.00%)	1 / 499 (0.20%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Radiculopathy			
subjects affected / exposed	0 / 247 (0.00%)	1 / 499 (0.20%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subarachnoid haemorrhage			
subjects affected / exposed	1 / 247 (0.40%)	0 / 499 (0.00%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syncope			
subjects affected / exposed	1 / 247 (0.40%)	2 / 499 (0.40%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transient ischaemic attack			
subjects affected / exposed	0 / 247 (0.00%)	1 / 499 (0.20%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	1 / 247 (0.40%)	0 / 499 (0.00%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ear and labyrinth disorders			

Sudden hearing loss			
subjects affected / exposed	0 / 247 (0.00%)	1 / 499 (0.20%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Cataract			
subjects affected / exposed	0 / 247 (0.00%)	1 / 499 (0.20%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal hernia			
subjects affected / exposed	0 / 247 (0.00%)	1 / 499 (0.20%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticulum intestinal			
subjects affected / exposed	0 / 247 (0.00%)	1 / 499 (0.20%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Duodenal ulcer			
subjects affected / exposed	0 / 247 (0.00%)	1 / 499 (0.20%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastric ulcer			
subjects affected / exposed	2 / 247 (0.81%)	0 / 499 (0.00%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroesophageal reflux disease			
subjects affected / exposed	1 / 247 (0.40%)	0 / 499 (0.00%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal obstruction			
subjects affected / exposed	0 / 247 (0.00%)	1 / 499 (0.20%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Oesophageal perforation			
subjects affected / exposed	1 / 247 (0.40%)	0 / 499 (0.00%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestinal obstruction			
subjects affected / exposed	0 / 247 (0.00%)	1 / 499 (0.20%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Cholecystitis			
subjects affected / exposed	0 / 247 (0.00%)	1 / 499 (0.20%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Diabetic foot			
subjects affected / exposed	0 / 247 (0.00%)	1 / 499 (0.20%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	1 / 247 (0.40%)	0 / 499 (0.00%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic kidney disease			
subjects affected / exposed	1 / 247 (0.40%)	0 / 499 (0.00%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nephrolithiasis			
subjects affected / exposed	0 / 247 (0.00%)	1 / 499 (0.20%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal failure			

subjects affected / exposed	1 / 247 (0.40%)	1 / 499 (0.20%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary retention			
subjects affected / exposed	0 / 247 (0.00%)	1 / 499 (0.20%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Arthritis			
subjects affected / exposed	1 / 247 (0.40%)	0 / 499 (0.00%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bursitis			
subjects affected / exposed	0 / 247 (0.00%)	1 / 499 (0.20%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteoarthritis			
subjects affected / exposed	0 / 247 (0.00%)	1 / 499 (0.20%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spondyloarthropathy			
subjects affected / exposed	0 / 247 (0.00%)	1 / 499 (0.20%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tendonitis			
subjects affected / exposed	0 / 247 (0.00%)	1 / 499 (0.20%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Arthritis bacterial			
subjects affected / exposed	1 / 247 (0.40%)	0 / 499 (0.00%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0



Diverticulitis			
subjects affected / exposed	0 / 247 (0.00%)	1 / 499 (0.20%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gangrene			
subjects affected / exposed	1 / 247 (0.40%)	0 / 499 (0.00%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infected skin ulcer			
subjects affected / exposed	1 / 247 (0.40%)	0 / 499 (0.00%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Klebsiella sepsis			
subjects affected / exposed	0 / 247 (0.00%)	1 / 499 (0.20%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	1 / 247 (0.40%)	2 / 499 (0.40%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Postoperative wound infection			
subjects affected / exposed	1 / 247 (0.40%)	0 / 499 (0.00%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	1 / 247 (0.40%)	0 / 499 (0.00%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	1 / 247 (0.40%)	0 / 499 (0.00%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urosepsis			

subjects affected / exposed	0 / 247 (0.00%)	1 / 499 (0.20%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Hypoglycaemia			
subjects affected / exposed	0 / 247 (0.00%)	1 / 499 (0.20%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	Extension Period: Bococizumab ADA positive	Extension Period: Bococizumab ADA negative	
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 33 (0.00%)	1 / 56 (1.79%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events	0	0	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Adenocarcinoma of colon			
subjects affected / exposed	0 / 33 (0.00%)	0 / 56 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bone cancer			
subjects affected / exposed	0 / 33 (0.00%)	0 / 56 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Breast cancer			
subjects affected / exposed	0 / 33 (0.00%)	0 / 56 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Breast cancer recurrent			
subjects affected / exposed	0 / 33 (0.00%)	0 / 56 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malignant melanoma			

subjects affected / exposed	0 / 33 (0.00%)	0 / 56 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Non-small cell lung cancer			
subjects affected / exposed	0 / 33 (0.00%)	0 / 56 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Plasma cell myeloma			
subjects affected / exposed	0 / 33 (0.00%)	0 / 56 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin cancer			
subjects affected / exposed	0 / 33 (0.00%)	0 / 56 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tonsil cancer			
subjects affected / exposed	0 / 33 (0.00%)	0 / 56 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Disease progression			
alternative dictionary used: MedDRA v20.0J			
subjects affected / exposed	0 / 33 (0.00%)	0 / 56 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			
Aortic aneurysm			
subjects affected / exposed	0 / 33 (0.00%)	0 / 56 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral artery dissection			
subjects affected / exposed	0 / 33 (0.00%)	0 / 56 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

General disorders and administration site conditions			
POSSIBLE SEIZURE DISORDER SECONDARY TO AMPHETAMINE ABUSE			
subjects affected / exposed	0 / 33 (0.00%)	0 / 56 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Asthenia			
subjects affected / exposed	0 / 33 (0.00%)	0 / 56 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chest pain			
subjects affected / exposed	0 / 33 (0.00%)	0 / 56 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Complication associated with device			
subjects affected / exposed	0 / 33 (0.00%)	0 / 56 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Death			
subjects affected / exposed	0 / 33 (0.00%)	0 / 56 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Non-cardiac chest pain			
subjects affected / exposed	0 / 33 (0.00%)	0 / 56 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyrexia			
subjects affected / exposed	0 / 33 (0.00%)	0 / 56 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular stent occlusion			

subjects affected / exposed	0 / 33 (0.00%)	0 / 56 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Acute respiratory distress syndrome			
subjects affected / exposed	0 / 33 (0.00%)	0 / 56 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Asthma			
subjects affected / exposed	0 / 33 (0.00%)	0 / 56 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 33 (0.00%)	0 / 56 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemoptysis			
subjects affected / exposed	0 / 33 (0.00%)	0 / 56 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary embolism			
subjects affected / exposed	0 / 33 (0.00%)	0 / 56 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary hypertension			
subjects affected / exposed	0 / 33 (0.00%)	0 / 56 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chest pain			
alternative dictionary used: MedDRA v20.0J			

subjects affected / exposed	0 / 33 (0.00%)	1 / 56 (1.79%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dyspnoea			
alternative dictionary used: MedDRA v 20.0J			
subjects affected / exposed	0 / 33 (0.00%)	1 / 56 (1.79%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychiatric disorders			
Depression			
subjects affected / exposed	0 / 33 (0.00%)	0 / 56 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Depression suicidal			
subjects affected / exposed	0 / 33 (0.00%)	0 / 56 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Paranoia			
subjects affected / exposed	0 / 33 (0.00%)	0 / 56 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychiatric decompensation			
subjects affected / exposed	0 / 33 (0.00%)	0 / 56 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Suicidal behaviour			
subjects affected / exposed	0 / 33 (0.00%)	0 / 56 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Investigations			
Gamma-glutamyltransferase increased			

subjects affected / exposed	0 / 33 (0.00%)	0 / 56 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Arterial injury			
subjects affected / exposed	0 / 33 (0.00%)	0 / 56 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
Acute myocardial infarction			
subjects affected / exposed	0 / 33 (0.00%)	0 / 56 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Angina pectoris			
subjects affected / exposed	0 / 33 (0.00%)	0 / 56 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Angina unstable			
subjects affected / exposed	0 / 33 (0.00%)	0 / 56 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arrhythmia			
subjects affected / exposed	0 / 33 (0.00%)	0 / 56 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrial fibrillation			
subjects affected / exposed	0 / 33 (0.00%)	0 / 56 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac failure			
subjects affected / exposed	0 / 33 (0.00%)	0 / 56 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Coronary artery disease			
subjects affected / exposed	0 / 33 (0.00%)	0 / 56 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coronary artery occlusion			
subjects affected / exposed	0 / 33 (0.00%)	0 / 56 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Left ventricular failure			
subjects affected / exposed	0 / 33 (0.00%)	0 / 56 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myocardial infarction			
subjects affected / exposed	0 / 33 (0.00%)	0 / 56 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sinus bradycardia			
subjects affected / exposed	0 / 33 (0.00%)	0 / 56 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sinus node dysfunction			
subjects affected / exposed	0 / 33 (0.00%)	0 / 56 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ventricular tachycardia			
subjects affected / exposed	0 / 33 (0.00%)	0 / 56 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrial fibrillation1			
alternative dictionary used: MedDRA 20.0J			
subjects affected / exposed	0 / 33 (0.00%)	0 / 56 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	



Myocardial ischaemia alternative dictionary used: MedDRA 20.0J subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 33 (0.00%) 0 / 0 0 / 0	0 / 56 (0.00%) 0 / 0 0 / 0	
Nervous system disorders Cerebral haematoma subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 33 (0.00%) 0 / 0 0 / 0	0 / 56 (0.00%) 0 / 0 0 / 0	
Cerebral haemorrhage subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 33 (0.00%) 0 / 0 0 / 0	0 / 56 (0.00%) 0 / 0 0 / 0	
Cerebrovascular accident subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 33 (0.00%) 0 / 0 0 / 0	0 / 56 (0.00%) 0 / 0 0 / 0	
Ischaemic stroke subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 33 (0.00%) 0 / 0 0 / 0	0 / 56 (0.00%) 0 / 0 0 / 0	
Miller Fisher syndrome subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 33 (0.00%) 0 / 0 0 / 0	0 / 56 (0.00%) 0 / 0 0 / 0	
Radiculopathy subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 33 (0.00%) 0 / 0 0 / 0	0 / 56 (0.00%) 0 / 0 0 / 0	
Subarachnoid haemorrhage subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 33 (0.00%) 0 / 0 0 / 0	0 / 56 (0.00%) 0 / 0 0 / 0	

Syncope			
subjects affected / exposed	0 / 33 (0.00%)	0 / 56 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transient ischaemic attack			
subjects affected / exposed	0 / 33 (0.00%)	0 / 56 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 33 (0.00%)	0 / 56 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ear and labyrinth disorders			
Sudden hearing loss			
subjects affected / exposed	0 / 33 (0.00%)	0 / 56 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eye disorders			
Cataract			
subjects affected / exposed	0 / 33 (0.00%)	0 / 56 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Abdominal hernia			
subjects affected / exposed	0 / 33 (0.00%)	0 / 56 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diverticulum intestinal			
subjects affected / exposed	0 / 33 (0.00%)	0 / 56 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Duodenal ulcer			

subjects affected / exposed	0 / 33 (0.00%)	0 / 56 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric ulcer			
subjects affected / exposed	0 / 33 (0.00%)	0 / 56 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 33 (0.00%)	0 / 56 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal obstruction			
subjects affected / exposed	0 / 33 (0.00%)	0 / 56 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal perforation			
subjects affected / exposed	0 / 33 (0.00%)	0 / 56 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Small intestinal obstruction			
subjects affected / exposed	0 / 33 (0.00%)	0 / 56 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
Cholecystitis			
subjects affected / exposed	0 / 33 (0.00%)	0 / 56 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin and subcutaneous tissue disorders			
Diabetic foot			
subjects affected / exposed	0 / 33 (0.00%)	0 / 56 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			

Acute kidney injury			
subjects affected / exposed	0 / 33 (0.00%)	0 / 56 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic kidney disease			
subjects affected / exposed	0 / 33 (0.00%)	0 / 56 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nephrolithiasis			
subjects affected / exposed	0 / 33 (0.00%)	0 / 56 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal failure			
subjects affected / exposed	0 / 33 (0.00%)	0 / 56 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary retention			
subjects affected / exposed	0 / 33 (0.00%)	0 / 56 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
Arthritis			
subjects affected / exposed	0 / 33 (0.00%)	0 / 56 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bursitis			
subjects affected / exposed	0 / 33 (0.00%)	0 / 56 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteoarthritis			
subjects affected / exposed	0 / 33 (0.00%)	0 / 56 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Spondyloarthropathy			
subjects affected / exposed	0 / 33 (0.00%)	0 / 56 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tendonitis			
subjects affected / exposed	0 / 33 (0.00%)	0 / 56 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Arthritis bacterial			
subjects affected / exposed	0 / 33 (0.00%)	0 / 56 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diverticulitis			
subjects affected / exposed	0 / 33 (0.00%)	0 / 56 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gangrene			
subjects affected / exposed	0 / 33 (0.00%)	0 / 56 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infected skin ulcer			
subjects affected / exposed	0 / 33 (0.00%)	0 / 56 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Klebsiella sepsis			
subjects affected / exposed	0 / 33 (0.00%)	0 / 56 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia			
subjects affected / exposed	0 / 33 (0.00%)	0 / 56 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Postoperative wound infection			

subjects affected / exposed	0 / 33 (0.00%)	0 / 56 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sepsis			
subjects affected / exposed	0 / 33 (0.00%)	0 / 56 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract infection			
subjects affected / exposed	0 / 33 (0.00%)	0 / 56 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urosepsis			
subjects affected / exposed	0 / 33 (0.00%)	0 / 56 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
Hypoglycaemia			
subjects affected / exposed	0 / 33 (0.00%)	0 / 56 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Placebo	Bococizumab (PF--04950615) 150 mg	Extension Period: Placebo
Total subjects affected by non-serious adverse events			
subjects affected / exposed	29 / 247 (11.74%)	97 / 499 (19.44%)	0 / 44 (0.00%)
General disorders and administration site conditions			
Injection site reaction	Additional description: For extension Period, NSAEs were not collected and hence actual population exposed is "0". Current presentation is a resolution of database limitation.		
alternative assessment type: Systematic			
subjects affected / exposed	2 / 247 (0.81%)	67 / 499 (13.43%)	0 / 44 (0.00%)
occurrences (all)	2	328	0
Infections and infestations			

Nasopharyngitis	Additional description: For extension Period, NSAEs were not collected and hence actual population exposed is "0". Current presentation is a resolution of database limitation.		
	alternative assessment type: Systematic		
subjects affected / exposed	14 / 247 (5.67%)	17 / 499 (3.41%)	0 / 44 (0.00%)
occurrences (all)	19	18	0
Upper respiratory tract infection	Additional description: For extension Period, NSAEs were not collected and hence actual population exposed is "0". Current presentation is a resolution of database limitation.		
	alternative assessment type: Systematic		
subjects affected / exposed	14 / 247 (5.67%)	18 / 499 (3.61%)	0 / 44 (0.00%)
occurrences (all)	16	21	0

Non-serious adverse events	Extension Period: Bococizumab ADA positive	Extension Period: Bococizumab ADA negative	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	0 / 33 (0.00%)	0 / 56 (0.00%)	
General disorders and administration site conditions			
	Additional description: For extension Period, NSAEs were not collected and hence actual population exposed is "0". Current presentation is a resolution of database limitation.		
Injection site reaction			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 33 (0.00%)	0 / 56 (0.00%)	
occurrences (all)	0	0	
Infections and infestations			
	Additional description: For extension Period, NSAEs were not collected and hence actual population exposed is "0". Current presentation is a resolution of database limitation.		
Nasopharyngitis			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 33 (0.00%)	0 / 56 (0.00%)	
occurrences (all)	0	0	
Upper respiratory tract infection	Additional description: For extension Period, NSAEs were not collected and hence actual population exposed is "0". Current presentation is a resolution of database limitation.		
	alternative assessment type: Systematic		
subjects affected / exposed	0 / 33 (0.00%)	0 / 56 (0.00%)	
occurrences (all)	0	0	

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
29 July 2014	Study follow-up period was reduced from 8 to 6 weeks.
17 May 2016	For US sites, addition of a substudy to provide additional follow up of subjects who were ADA positive at the last study visit.
07 July 2016	For US sites, addition of a substudy that provides additional follow-up of subjects who were ADA positive and information on use of concomitant medication, LDL-C, and to not discontinue subjects who start treatment with a PCSK9 inhibitor.

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported